Bristol Myers Squibb Declares Dividend as Barclays Rates Stock Overweight
Bristol Myers Squibb declared a quarterly cash dividend, underscoring its commitment to shareholder returns. Barclays initiated coverage of the company with an Overweight rating, highlighting AI-driven drug discovery efficiencies that compress development timelines and reduce costs for its deep pipeline.
1. Dividend Announcement
Bristol Myers Squibb's board declared a quarterly cash dividend, underscoring its commitment to returning capital to shareholders.
2. Barclays Overweight Rating
Barclays launched coverage of U.S. large-cap biopharma with a Neutral sector view and assigned Bristol Myers Squibb an Overweight rating, citing AI-driven drug discovery efficiencies that compress development timelines and reduce costs for companies with robust pipelines.
Related News
NVDA
Nvidia Raises July Quarter Guidance, Forecasts $91B Fiscal 2027 Revenue
NVDA•
INTC
Nvidia’s $91B AI Forecast, $80B Buyback Ramps Up Pressure on Intel
INTC•
MA
Chargebacks911 Partners with acceptcards to Reduce Chargebacks as UK Card Use Tops £1 Trn
MA•
META
Meta Lays Off 10% Workforce, Cancels 6,000 Hires as AI Capex Jumps
META•
NVDA
Nvidia Targets $200 Billion Agentic AI Market with Vera CPU Launch
NVDA•
Sources
BFG